Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna ...

Moderna will slash five clinical programmes but says it remains on track for ten product approvals in the next three years.

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Moderna MRNA announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly ...

Moderna announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly pointed to ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Drug maker Moderna, Inc. (MRNA), at its annual R&D Day event on Thursday, presented its outlook for fiscal 2025 and beyond, as well ...

Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna (NASDAQ:MRNA) shares continued to tumble in the pre-market on Friday as J.P ...